Form 4: AN2 Therapeutics Director Acquires Shares in Lieu of Cash Compensation

Director Joseph S. Zakrzewski acquired 10,523 shares of AN2 Therapeutics common stock in lieu of cash compensation on April 10, 2025.

Summary

• On April 10, 2025, Joseph S. Zakrzewski, a director of AN2 Therapeutics, Inc., acquired 10,523 shares of common stock.
• The shares were issued in lieu of cash compensation under the company's non-employee director compensation policy, and they vest immediately.
• Following the transaction, Zakrzewski directly owns 145,538 shares and indirectly owns 405,880 shares through the Z3 Trust, for which he serves as trustee.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine transaction (director compensation) and doesn't indicate any significant positive or negative development for the company.

Positives

• The acquisition of shares by a director demonstrates confidence in the company.
• The use of shares in lieu of cash compensation can conserve company cash resources.

Industry Context

Directors receiving stock in lieu of cash compensation is a fairly common practice, especially for smaller companies, to align director interests with shareholders and conserve cash.

Stakeholder Impact

• The transaction could have a slightly dilutive effect on existing shareholders, although the number of shares is relatively small.
• It aligns the director's interests with those of the shareholders.

Key Dates

Keywords

AN2 Therapeutics, Director, Share Acquisition, Form 4, Compensation, ANTX, Zakrzewski, Beneficial Ownership